A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01316601

Enrollment

Registered

2011-03-16

Start date

2011-01-31

Completion date

2012-11-30

Last updated

2015-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Brief summary

Test safety and efficacy and of a novel IL-13 AB in the treatment of perianal fistulas * Trial with medicinal product

Interventions

DRUGQAX567

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

- diagnosis of Crohn's disease \> 6 month with fistula - at least 1 ineffective fistula treatment in the past

Exclusion criteria

- TNF a antibody treatment failed in the past \- planned surgery

Design outcomes

Primary

Measure	Time frame
complete closure of fistula	—

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026